Subramani, B.; Conway, P.J.; Al-Khinji, A.; Zhang, K.; Pandey, R.; Mahadevan, D.
A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma. Cancers 2024, 16, 4257.
https://doi.org/10.3390/cancers16244257
AMA Style
Subramani B, Conway PJ, Al-Khinji A, Zhang K, Pandey R, Mahadevan D.
A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma. Cancers. 2024; 16(24):4257.
https://doi.org/10.3390/cancers16244257
Chicago/Turabian Style
Subramani, Baskaran, Patrick J. Conway, Aisha Al-Khinji, Kun Zhang, Ritu Pandey, and Daruka Mahadevan.
2024. "A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma" Cancers 16, no. 24: 4257.
https://doi.org/10.3390/cancers16244257
APA Style
Subramani, B., Conway, P. J., Al-Khinji, A., Zhang, K., Pandey, R., & Mahadevan, D.
(2024). A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma. Cancers, 16(24), 4257.
https://doi.org/10.3390/cancers16244257